221148-27-2Relevant academic research and scientific papers
USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS
-
Page/Page column 30, (2008/06/13)
The invention concerns the use of compounds of formula (I), (II) and (III): which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts or solvates thereof, for the treatment of depressive disorders in combination with an effective amount of a second component which is a selective serotonin reuptake inhibitor.
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors
Beswick, Paul,Bingham, Sharon,Bountra, Chas,Brown, Terry,Browning, Kerry,Campbell, Ian,Chessell, Iain,Clayton, Nick,Collins, Sue,Corfield, John,Guntrip, Stephen,Haslam, Claudine,Lambeth, Paul,Lucas, Fiona,Mathews, Neil,Murkit, Graham,Naylor, Alan,Pegg, Neil,Pickup, Elizabeth,Player, Hazel,Price, Helen,Stevens, Alexander,Stratton, Sharon,Wiseman, Joanne
, p. 5445 - 5448 (2007/10/03)
GW406381 (8), currently undergoing clinical evaluation for the treatment of inflammatory pain is a member of a novel series of 2,3-diaryl-pyrazolo[1,5-b] pyridazine based cyclooxygenase-2 (COX-2) inhibitors, which have been shown to be highly potent and selective. Several examples of the series, in addition to possessing favourable pharmacokinetic profiles and analgesic activity in vivo, have also demonstrated relatively high brain penetration in the rat compared with the clinically available compounds, which may ultimately prove beneficial in the treatment of pain.
